Paricalcitol Improves Anemia of Inflammation

Inclusion Criteria: * Age \>= 18 years. * Patients with CKD on hemodialysis of any etiology.. * Hemoglobin between 9 and 12g/dl at least 12 weeks before enrollment in the study. * Hemoglobin plasma levels stabilized: Hb variation \<or = 1 g / dl for the two months prior to inclusion in the study. * Patients with anemia of renal etiology. * ESA treatment with stable doses for 2 months prior to baseline.Stable dose ESA Definition: Variation \<or = 3000UI/week. * Iron status: Ferritin\> 200 ng / mL and/or transferrin saturation index (IST):\> = 20%). * KT / V \>= 1.2 ( Daugirdas-2nd generation). * Calcium concentrations between : 8.4 to 9.5 mg / dl and phosphorus: 3.5-5.5 mg / dl. * Vitamin D 25OH normal \>= 15 ng / ml (patients with lower levels will be supplemented with calcifediol 16000 IU / bi-weekly for 6 weeks in selected patients). * PTHi concentrations\> = 150 pg / mL and \<or = to 300 pg / ml. * Patients who accept their inclusion in the study and sign informed consent. Exclusion Criteria: * Epoetin beta dose \> 18,000 IU / weekly. * Pregnant woman of childbearing age or gestational wishes or not to use adequate contraception ( the Ogino-Knaus contraceptive method is considered unsuitable). * Active bleeding episode or history of transfusion the 2 months prior to baseline. * Patients with non-renal causes of anemia: malignancies, folic acid or vitamin B12 deficiency, hemoglobinopathies, hemolysis, pure red cell aplasia secondary to erythropoietin. * Patients treated with the selective vitamin D receptor activator in the 3 months prior to inclusion in the study. * Acute or chronic symptomatic: heart failure (IV-NYHA), infection or inflammatory disease, uncontrolled hypertension that requires the suspension of epoetin beta, thrombocytopathies, aplastic anemia. * Immunosuppressive treatment with uncontrolled Hemoglobin level * Allergy to paricalcitol or any of its components.